In addition, chimeric antigen receptor T-Cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) expressed on malignant plasma cells has shown clear evidence of efficacy in patients with MM [5] but high individual costs [6], an extended manufacturing process, and adverse effects (cytokine release syndrome and neurotoxicity) limit accessibility to CAR-T therapy in patients with MM [7]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.